HeartBeam, Inc.
corporate_fare Company Profile
HeartBeam, Inc. (NASDAQ:BEAT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 35 items for BEAT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for BEAT spans 10-Q, 8-K, SCHEDULE 13D/A, 8-K/A.
Recent high-impact activity:
- HeartBeam Q3 10-Q: $6.1M Cash, Going Concern Warning, Nasdaq Bid Deficiency
- Q3 Net Loss Narrows to $3.0M as HeartBeam Cuts Cash Burn and Extends Runway Into 2027
- HeartBeam's 3D ECG Matches Standard 12-Lead in Heart Attack Pilot, Pivotal Study Set for Q1 2027
- FDA Accepts HeartBeam's 3D ECG System Into TAP Pilot; Pivotal Study Enrollment Set for Q1 2027
- HeartBeam Soars 62% After FDA Breakthrough Designation for At-Home Heart Attack Test
Financial Snapshot
Short Interest & Short Volume
1.60 days to coverFINRA reported short interest of 2,269,661 shares in BEAT as of the October 30, 2026 settlement, a 8.6% decrease from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 43.9% of BEAT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for BEAT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.
ATM Sales Agreement Signed · Funding Amid Going Concern
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →